What are the 1-year returns of Tata India Pharma & Healthcare Fund Direct-Growth?
Tata India Pharma & Healthcare Fund Direct-Growth has delivered a 1-year return of 10.23% as of 6 Sep 2026. During the same period, its benchmark BSE Healthcare Total Return Index returned 22.74%. The fund has underperformed its benchmark over this period.
What are the 3-year returns of Tata India Pharma & Healthcare Fund Direct-Growth?
Tata India Pharma & Healthcare Fund Direct-Growth has delivered a 3-year CAGR of 19.95% as of 6 Sep 2026. Its benchmark BSE Healthcare Total Return Index returned 47.28% CAGR over the same period. CAGR (Compounded Annual Growth Rate) is the right way to evaluate multi-year mutual fund performance as it smooths out year-to-year volatility.
What are the 5-year returns of Tata India Pharma & Healthcare Fund Direct-Growth?
Tata India Pharma & Healthcare Fund Direct-Growth has delivered a 5-year CAGR of 14.76% as of 6 Sep 2026. Its benchmark BSE Healthcare Total Return Index returned 13.97% CAGR over the same period. A 5-year track record is considered a more reliable indicator of fund quality than shorter-term performance, as it captures at least one full market cycle.
What are the returns of Tata India Pharma & Healthcare Fund Direct-Growth since inception?
Since its launch on 3 Jan 2016, Tata India Pharma & Healthcare Fund Direct-Growth has delivered a CAGR of 13.71%. Since-inception returns reflect the fund's full history and give the most complete picture of long-term performance.
How has Tata India Pharma & Healthcare Fund Direct-Growth performed vs its category over the long term?
Over the long term, Tata India Pharma & Healthcare Fund Direct-Growth has ranked 9 out of 11 funds in the Equity: Sectoral-Pharma category on a 3-year basis, and 5 out of 8 funds on a 5-year basis. Category rank is one of several factors to consider alongside risk metrics and rolling return consistency when evaluating a fund.
What is the Sharpe ratio of Tata India Pharma & Healthcare Fund Direct-Growth?
The Sharpe ratio of Tata India Pharma & Healthcare Fund Direct-Growth is 0.92 (as of 6 Sep 2026). The Sharpe ratio measures how much return the fund generates per unit of risk (volatility) taken. A Sharpe ratio above 1.0 is generally considered good — the higher the ratio, the better the risk-adjusted return.
What is the alpha of Tata India Pharma & Healthcare Fund Direct-Growth?
The 3Y alpha of Tata India Pharma & Healthcare Fund Direct-Growth is -1.55% (as of 6 Sep 2026). Alpha measures the excess return generated by the fund over and above its benchmark BSE Healthcare Total Return Index, after adjusting for risk. A positive alpha means the fund manager has added value beyond what the market delivered. A negative alpha means the fund has underperformed its benchmark on a risk-adjusted basis.
What is the beta of Tata India Pharma & Healthcare Fund Direct-Growth?
The beta of Tata India Pharma & Healthcare Fund Direct-Growth is 0.99 (as of 6 Sep 2026). Beta measures how sensitive the fund is to market movements relative to its benchmark BSE Healthcare Total Return Index. A beta of 1 means the fund moves in line with the market. A beta above 1 means it is more volatile than the market; below 1 means it is less volatile. Tata India Pharma & Healthcare Fund Direct-Growth's beta of 0.99 indicates it is more defensive than its benchmark.
What are the rolling returns of Tata India Pharma & Healthcare Fund Direct-Growth?
The average 1-year and 3-year rolling returns of Tata India Pharma & Healthcare Fund Direct-Growth is 17.06% and 18.50% respectively. Rolling returns show the fund's annualized return across every possible 1-year and 3-year investment window, making them a far more reliable measure of consistency than point-to-point returns, which depend heavily on the start and end date chosen.
